The Discovery of Viagra
Sildenafil, From Angina Failure to the Little Blue Pill (1989-1998)
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Sildenafil FDA Approved for ED (March 1998)
Reference only. Not medical advice.
What can go wrong
Sildenafil is contraindicated with nitrates, where combined vasodilation can cause dangerous hypotension. Historically this drug-class interaction shaped ED prescribing safety standards. Common effects include headache, flushing, dyspepsia, and visual color changes. This is a historical/biographical entry; clinical use requires physician evaluation.
This is something to take to a clinician. The Atlas can tell you what is known about the discovery of viagra in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Sildenafil (UK-92,480) was developed at Pfizer's Sandwich, Kent laboratory in the late 1980s as a candidate treatment for angina and hypertension, targeting the PDE5 enzyme to relax blood vessels. The cardiovascular effect was modest, but trial volunteers reported a striking side effect, penile erections. Pfizer pivoted the program toward erectile dysfunction, and on March 27, 1998 the FDA approved Viagra, the first effective oral ED drug, launching the modern era of sexual medicine.
The accidental side effect that became a billion-dollar medicine.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in penile smooth muscle. With cGMP preserved, smooth muscle stays relaxed and the corpora cavernosa fill with blood during arousal. The same vasodilatory action explains its original cardiovascular development and its later use in pulmonary hypertension.
What people get wrong
Often saidViagra was invented as a sex drug
ActuallyIt was developed as a heart medication for angina. The erectile effect was an unplanned trial observation that redirected the entire program.
Often saidViagra creates an erection on its own
ActuallyIt enables an erection in response to sexual arousal by blocking PDE5; without arousal and nitric oxide signaling it does little.
Who profits, and who pushes back
Leonore Tiefer
Viagra's launch reframed ordinary variation in male sexual response as a treatable disease, fueling demand and recasting a complex relational experience as a pharmacological deficit.
Meika Loe
The drug's marketing helped standardize a narrow performance-centered model of male sexuality and expanded the market by drawing in men without clear organic pathology.
Pharmacovigilance and safety reviewers
The rapid blockbuster uptake outpaced understanding of risks such as nitrate interactions and rare non-arteritic anterior ischemic optic neuropathy, which surfaced largely after mass adoption.
How we got here
In the mid-1980s, medicinal chemists at Pfizer's Sandwich, Kent laboratory in the United Kingdom were pursuing inhibitors of phosphodiesterase type 5 (PDE5) as a way to relax vascular smooth muscle and treat angina pectoris, chest pain from reduced cardiac blood flow. By 1989 the team had synthesized the compound UK-92,480, later named sildenafil citrate. In early clinical trials the anti-anginal effect proved underwhelming, and the short half-life made it a poor cardiovascular drug. But trial participants, particularly in a study at the Morriston Hospital in Swansea, Wales, reported an unexpected and persistent side effect, erections. Pfizer scientists recognized the mechanism: PDE5 is highly concentrated in penile tissue, where blocking it preserves cyclic GMP and sustains the smooth-muscle relaxation that lets blood fill the corpora cavernosa. The company redirected the program toward erectile dysfunction, a condition that had until then been treated mainly with injections, vacuum devices, and implants. After successful efficacy trials, the FDA approved Viagra on March 27, 1998. The launch was a cultural and commercial phenomenon: Viagra became one of the fastest-selling drugs in history, destigmatized male sexual dysfunction, and effectively created the field of pharmacologic sexual medicine. Sildenafil's PDE5 mechanism was later separately developed for pulmonary arterial hypertension under the name Revatio.
- Mid-1980sPfizer Sandwich (UK) pursues PDE5 inhibitors for angina
- 1989Sildenafil (UK-92,480) synthesized
- Early 1990sAngina trials disappoint; volunteers report erections as a side effect
- 1994Program formally redirected toward erectile dysfunction
- 1996U.S. patent granted
- March 27, 1998FDA approves Viagra for ED, the first oral ED drug
- 1998EU approval; record-breaking commercial launch
- 2017-2020Generic sildenafil widely available
Set against the alternatives
Viagra's discovery is the archetypal case of serendipitous drug repurposing, comparable to minoxidil (developed for hypertension, repurposed for hair loss) and bupropion (an antidepressant later used for smoking cessation). Unlike those, sildenafil created an entirely new mass market essentially overnight and triggered a competitive PDE5 race: Bayer/GSK's vardenafil (Levitra) and Lilly/ICOS's tadalafil (Cialis) both arrived in 2003, with tadalafil differentiating on its long 36-hour window, and Vivus's avanafil (Stendra) following in 2012 with the fastest onset. Against later mechanistically distinct options such as intracavernosal injection or penile prosthesis, the Viagra breakthrough mattered most for shifting ED treatment from invasive, clinic-bound procedures to a discreet oral pill.
| Drug | Brand | FDA approval | Maker |
|---|---|---|---|
| Sildenafil | Viagra | 1998 | Pfizer |
| Vardenafil | Levitra | 2003 | Bayer / GSK |
| Tadalafil | Cialis | 2003 | Lilly / ICOS |
| Avanafil | Stendra | 2012 | Vivus / Mitsubishi Tanabe |
What we do not know
- Would the erectile side effect have been pursued at all under today's more rigid, indication-locked trial designs?
- How much did Viagra's launch genuinely expand recognition of underlying vascular disease versus simply expand drug demand?
- What is the full long-term safety profile of decades of population-scale PDE5 exposure, including any neurological signals?
- How transferable is the serendipity-then-pivot model to current target-driven, AI-guided drug discovery pipelines?
What could change
Historical reassessmentOngoing scholarship reframing the discovery within debates on medicalization and gendered marketingRepurposing legacySildenafil itself now studied for pulmonary hypertension, Raynaud, and possible neuroprotection, extending the original pivotDiscovery-model influenceThe case continues to inform how pharma evaluates unexpected trial side effects as opportunities
At a glance
- Compound code
- UK-92,480
- Synthesized
- 1989
- Research site
- Sandwich, Kent, UK
- FDA approval for ED
- March 27, 1998
- Original target indication
- Angina / hypertension
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The Discovery of Viagra. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA approval of Viagra (sildenafil)1998
First oral agent shown effective for erectile dysfunction in randomized trials, defining the PDE5-inhibitor class